ETV6/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia

Journal of Hematopathology

Volumn 7, Issue 2, 2014, Pages 71-77

  Hosseini, Niloufar ^a   Craddock, Kenneth J ^a   Salehi rad, Shabnam ^a   Brennan, Shawn ^a   Bailey, Denis J ^a   Brandwein, Joseph M ^b   Porwit, Anna ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ETV6; FLT3; Mixed lineage acute leukemia; Myeloproliferative disorders

Indexed keywords

EID: 84903904790     PISSN: None     EISSN: 18655785     Source Type: Journal    
DOI: 10.1007/s12308-014-0203-6     Document Type: Article

References (11)

1. Bain BJ, Gilliland DG, Horny HP et al (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 68-73.
2. Cools J, DeAngelo DL, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13): 1201-1214.
3. Vu HA, Xinh PT, Masuda M et al (2006) FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 20: 1414-1421.
4. Walz C, Erben P, Ritter M et al (2011) Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 118: 2239-2242.
5. Kantarjian HM, O'Brien S, Smith TL et al (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18: 547-561.
6. Lichter P, Cremer T (1992) Chromosome analysis by non-isotopic in situ hybridization. In: Rooney DE, Czepulkowski BH (eds) Human cytogenetics: a practical approach, 2nd edn. Oxford University Press, New York, p 157.
7. Metzgeroth G, Walz C, Erben P et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143(5): 707-715.
8. David M, Cross NC, Burgstaller S et al (2007) Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109(1): 61-64.
9. De Braekeleer E et al (2012) ETV6 fusion genes in hematological malignancies: a review. Leuk Res 36(8): 945-961.
10. Jackson CC, Medeiros LJ, Miranda RN (2010) 8p11 myeloproliferative syndrome: a review. Hum Pathol 41(4): 461-476.
11. Huang Q, Snyder DS, Chu P et al (2011) PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia. Leukemia 25(2): 371-375.